Santacruzamate A

Key Product Details

Product Description

Santacruzamate A is a highly potent and selective histone deactylase 2 (HDAC2) inhibitor (IC₅₀ = 112 - 119 pM). Also inhibits HDAC6 in nanomolar range (IC₅₀ = 433 nM). Displays >3500 fold selectivity for HDAC2 over HDAC6, and >8500-fold selectivity over HDAC4 (IC₅₀ >1 μM for HDAC4). Inhibits growth of HuT-78 cutaneous T-cell lymphoma cell line. Identified as targeting human host proteins that interact with SARS-CoV-2.

Product Specifications for Santacruzamate A

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Santacruzamate A

The following data is based on the product molecular weight 278.35.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.59 mL	17.96 mL	35.93 mL
5 mM	0.72 mL	3.59 mL	7.19 mL
10 mM	0.36 mL	1.80 mL	3.59 mL
50 mM	0.07 mL	0.36 mL	0.72 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Gordon A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020 PMID: 32353859
• Pavlik Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J.Nat.Prod. 2013 PMID: 24164245

Product Documents for Santacruzamate A